Overall, the synergic combination of Keap1-Nrf2 inhibitors and H2S donors has the potential for ulcerative colitis treatment, and molecular hybridization may be a promising strategy for the therapy of multifactorial inflammatory disease. This evidence concerns the gene NFE2L2 and ulcerative colitis.